We are developing a portfolio of novel therapeutics targeting metabolic diseases. Substantial unmet needs persist in obesity, particularly in achieving sustained weight loss and in addressing the key underlying pathologies that impact cardiometabolic health outcomes. Alveus aims to address these critical issues, delivering meaningful improvements in patient outcomes. In addition to our lead program, we are advancing an amylin pipeline of highly differentiated small molecules, peptides, and novel formats across multiple indications.
Competitive in vitro potency and weight loss with lean mass preservation in obese non-human primates. Weight loss and weight maintenance demonstrated in Ph1 clinical trial.
GIPR antagonism enhances the weight loss effects of GLP-1R agonism and may allow for infrequent dosing.
Novel recombinant humanized GIPR antagonist IgG-4 antibody – GLP-1R agonist peptide fusion protein.
High in vitro potency on human AMYR3 with significant selectivity over human CTR. Weight loss and food intake reduction efficacy in diet-induced obese rats. Pharmacokinetic profile in preclinical models indicate a once weekly profile.
Selective targeting of AMYR3 to induce weight loss efficacy and lean mass preservation with improved tolerability compared to DACRAs.
Selective lipidated AMYR3 peptide.